Maroney Dawn Christine sold $70K of ALHC

Maroney Dawn Christine (President) sold 5,000 shares of Alignment Healthcare, Inc. (ALHC) at $14.00 on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maroney Dawn Christine
Published Aug 18, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
high confidence
Mentioned
$ALHC
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not include new operational, financial, or regulatory information.

02

Market read

Traders may note insider selling activity, but the 10b5-1 pre-arranged nature makes it a low-signal catalyst.

03

What to watch

The filing does not disclose reasons for the sale, and the share count ($70k) may be small relative to company size, limiting interpretability.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-14

Background

This is an SEC Form 4 insider transaction for Alignment Healthcare, Inc., reported by its President.

Company-level read

Ticker impact

$ALHCNeutralHigh confidence
Context

Alignment Healthcare disclosed an insider open-market sale by President Maroney Dawn Christine of 5,000 shares at $14 on 2026-08-14.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction is likely muted.

Evidence & confidence

The transaction is explicitly coded as an open-market sale and states a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution about near-term execution or liquidity needs.

Key entities

  • Alignment Healthcare, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Maroney Dawn Christine

    President and reporting insider who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMedAI 8/10

Alignment Healthcare (ALHC) Q3 2026 Earnings Call Transcript

Alignment Healthcare (ALHC) reported Q3 2026 earnings, with revenue of $1.4B (up 37% YoY) and adjusted gross profit of $142M. The company lowered annual guidance due to higher costs, targeting adjusted gross profit of at least $575M and adjusted EBITDA of $100M. Membership grew 31% YoY to 301,200. ALHC is addressing cost pressures and investing in clinical programs for 2027 growth.

$ALHCMedAI 8/10

What Alignment Healthcare (ALHC) Said on Its Q3 Earnings Call

Alignment Healthcare (ALHC) reduced its 2026 outlook, expecting at least $5.25B revenue, $575M adjusted gross profit, and $100M adjusted EBITDA. Q4 forecasts include 305K membership, $1.32B revenue, and $104M gross profit. Management targets 20% top-line growth in 2027, with plans to enter new markets and improve care model scalability. Stars ratings and provider alignment remain focus areas.